these data support the possibility of achieving csf levels of ril-2 that are adequate to maintain activity of lymphokine-activated killer cells after parenteral administration , and argue for ril-2-associated disruption of the human blood-brain barrier in some patients .
C0021756
ril-2
C0218986
ril-2